FDA Approves Neuralstem to Treat Final Cohort in NSI-189 Phase Ib Trial in …

FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In …
ROCKVILLE, Md., April 22, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test … Read more on PR Newswire (press release)

NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System …
After 18 weeks of eTNS therapy, 40.5% of patients in the treatment group had a reduction in seizures of at least 50%. In addition to clinical trials in epilepsy, NeuroSigma has funded clinical trials at UCLA for the treatment of major depression, PTSD … Read more on PR Newswire (press release)

Video 68.wmv serotonin and addiction – serotonin and addiction major depression treatment resistant depression whats worked for me.